Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company specializing in novel therapeutics for degenerative retinal diseases, has scheduled a webcast for Monday, August 11, 2025, at 4:30 p.m. Eastern Time. During this event, the company will discuss its Q2 2025 financial results and provide a business update for the quarter ended June 30, 2025.
The webcast will be accessible through the company's investor relations website, and a replay will remain available for approximately 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – BLTE
On the day this news was published, BLTE gained 6.19%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $124M to the company's valuation, bringing the market cap to $2.12B at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the second quarter ended June 30, 2025.
Webcast Information
Date: Monday, August 11, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/127464226
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) hosting its Q2 2025 earnings webcast?
How can investors access Belite Bio's Q2 2025 earnings webcast?
How long will the replay of Belite Bio's Q2 2025 earnings webcast be available?
What is Belite Bio's main business focus?
